Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
CAMBRIDGE, Mass., Feb. 10, 2017 -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will present a company overview at two upcoming investor conferences in February. Details of the presentations are as follows:
| 19th Annual BIO CEO & Investor Conference | |
| Date: | Monday, February 13, 2017 |
| Time: | 3:00 p.m. ET |
| Location: | New York City |
| RBC Capital Markets 2017 Global Healthcare Conference | |
| Date: | Wednesday, February 22, 2017 |
| Time: | 10:30 a.m. ET |
| Location: | New York City |
Live webcasts of the presentations will be available on the Investors & Media section of the Editas website at www.editasmedicine.com. Archived replays will be available for approximately 30 days following the respective presentations.
About Editas Medicine
Editas Medicine is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting their disease-causing genes. The company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.
Media Contact Dan Budwick Pure Communications, Inc. (973) 271-6085 [email protected] Investor Contact Mark Mullikin Editas Medicine, Inc. (617) 401-9083 [email protected]
